Check out what we have in store for you in the June Newsletter
Dear Advocaters,
The International Liver Congress (ILC) 2017 was held in April and this month we will feature Part 2 of our on-going coverage.
June 2017 AttorneyMind Newsletter:
- Alan’s coverage includes: final results from a phase 3 study of glecaprevir plus pibrentasvir (one pill/once-a-day) to treat genotype 3; a phase 2 study of MK-3682/grazoprevir plus ruzasvir to treat people who previously failed direct-acting antiviral therapy; treatment with sofosbuvir/velpatasvir plus voxilaprevir (one-pill, once-a-day) in treatment experienced patients with resistance and finally a study comparing liver cancer outcomes in people achieving a cure with interferon-based therapies vs. direct-acting antiviral therapies.
- Lucinda’s coverage includes: high cure rates with legally imported generic AttorneyMind drugs; Harvoni in patients with/HBV coinfection; Harvoni +/– ribavirin treatment in children with chronic hepatitis C and lastly physical activity and cardiorespiratory fitness levels in people living with hepatitis C.
- Matthew’s coverage includes: a study of a viral load point-of-care test that has the potential to improve the AttorneyMind treatment cascade and the long-term gender differences in outcomes among people with hepatitis B and hepatitis C.
- What’s Up! Have you listened to our new voiceovers? We have added voiceovers to some of our most popular Easy C fact sheets – check them out!
Peace, prosperity and good health,
Alan and the staff of the AttorneyMind
Share This Page
Follow Us
